Skip to mainSkip to footer

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

Author(s)
Fabienne CRETIN-FUMERON,Stéphane DIEUDONNÉ
Published on
10 July 2024
Read time
8 minute(s) read

Dear investors,

The Merger Arbitrage strategy had a rather paradoxical second quarter in 2024.

On the one hand, all the signs were positive at the start of the year: a strong upturn in M&A activity with, in particular, a return to deals over $10bn, attractive yields, deal failure rates below the historical average and a few increased bids.

However, the performance of the strategy was disappointing. The HFRX index fell by 2.6% over the quarter. Against this difficult backdrop, we managed to preserve the capital of our funds with positive performances of 0.26% for Carmignac Portfolio Merger Arbitrage (I EUR Acc shareclass) and 0.71% for Carmignac Portfolio Merger Arbitrage Plus (I EUR Acc shareclass). But these performances are still below the cost of financing, which is also, in a way, a disappointment.

Several factors may explain this paradox.

First, a series of idiosyncratic events disrupted the trajectory of some spreads that were widely held by other arbitrageurs. We can cite three examples.

The first is obviously Tapestry's acquisition of Capri in the US handbag sector. In April, against all expectations, the FTC ruled that the merger posed a risk of price increases in a market segment with low barriers to entry. Capri's shares fell sharply during the quarter to a level close to the one estimated in the event of the deal's failure. The case is now in court, with a ruling expected in September.

The second is Chevron's acquisition of Hess, another oil company. The spread has proved highly volatile under the combined effect of geopolitical tensions in Guyana, dissatisfaction with the price among some shareholders and the ongoing dispute between Chevron and Exxon. If all goes well, the deal should be finalised before the end of the year.

The third example is the acquisition of the British packaging company DS Smith. The buyer, International Paper, which was to pay with its own shares, was itself the subject of a bid proposal from the Brazilian company Suzano. The DS Smith/International Paper spread, fell sharply, partly as a result of the rise in International Paper's share price. At the end of the quarter, Suzano announced that it was dropping its acquisition plans, which resulted in a significant tightening of the DS Smith/International Paper spread.

All in all, although these three events did not result in the failure of the deals concerned, however, the resulting volatility left its mark on Merger Arbitrage's portfolios.

Another factor explaining the paradox of a disappointing performance in a buoyant environment is that, under pressure from the competition authorities, particularly in the United States, deals are taking longer to be finalised. The impact of a deal taking longer than expected can be significant for the arbitrageur. In fact, it sometimes only takes a quarter's delay for the annualised return on a deal to end up below the cost of capital.

While an in-depth study known as a 2nd Request used to be the exception in the FTC's analysis process, it now seems to have become the rule. As a result, even transactions presenting only a low antitrust risk must now undergo a 2nd Request, which may lead to court action.

Recent examples include the Hess/Chevron and Pioneer Natural Resources/Exxon Mobil transactions in the oil sector, both of which were the subject of in-depth investigations despite the fact that there were almost no competition concerns in either case. In the healthcare sector, we might also mention two deals, Catalent/Novo Holding and Cerevel Therapeutics/AbbVie, currently in 2nd request. Although this is a sensitive sector in the eyes of the competition authorities, these two transactions do not seem to us to represent a major risk for the American consumer.

Since her appointment, the new chair of the FTC has consistently stated that she wants to strengthen the role of the competition authorities. While the FTC was unsuccessful in several court cases last year (Activision and Horizon Therapeutics), it has to be recognised that the pressure on M&A transactions between US players has increased. With the presidential election looming, a political dimension has undeniably been added to the purely industrial and strategic analysis carried out by the FTC.

In its latest monthly commentary on Merger Arbitration, Morgan Stanley noted that some fifteen deals were currently under in-depth investigation, compared with an average of half that number over the previous 4 years.

In the end, as the market did not fully anticipate this change of regime at the start of the year, returns on a number of deals ended up being lower than expected due to the longer duration of the deals.

The final factor explaining the paradox is technical.

In this environment, where deals can be more volatile or take longer than expected, some multi-asset funds with very tight risk constraints have had to scale back or even close Merger Arbitrage portfolios. Bloomberg reports that Millenium closed a Merger Arbitrage pod in April following performance problems with Capri and US Steel, and that Balyasny AM and Schonfeld Strategic Advisors did the same in June.

The closure of these Merger Arbitrage funds means that the least liquid spreads have widened, without any specific fundamental news. This self-sustaining liquidity phenomenon explains part of the underperformance of the Merger Arbitrage strategy during the quarter.

For the second half of the year, we remain confident for several reasons:

  • The portfolio's embedded yield is at historically high levels.
  • M&A activity, although slowing slightly ahead of the US elections, is continuing on a solid trajectory, which should make 2024 a year of recovery for the cycle.
  • The market is now more cautious in its estimates of the duration of new deals announced, which should limit the negative impact of any extension on expected returns.
  • The companies themselves have also taken account the more difficult antitrust environment when announcing deals, which should probably reduce the risk of a 2nd Request in the future.

The Merger Arbitrage Team

Carmignac Portfolio Merger Arbitrage Plus I EUR Acc

ISIN: LU2585801330
Recommended minimum investment horizon
3 years
Risk indicator*
2/7
SFDR - Fund Classification**
Article 8

*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **Sustainable Finance Disclosure Regulation (SFDR) 2019/2088. The SFDR classification of the Funds may change over time.

Main risks of the fund

Equity: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.
Arbitrage: Arbitrage seeks to benefit from such price differences (e.g. in markets, sectors, securities, currencies). If arbitrage performs unfavorably, an investment may lose its value and generate a loss for the Sub-Fund.
Risk associated with the Long/Short Strategy: This risk is linked to long and/or short positions designed to adjust net market exposure. The Fund may suffer high losses if its long and short positions undergo simultaneous unfavourable development in opposite directions.
Liquidity: Temporary market distortions may have an impact on the pricing conditions under which the Fund might be caused to liquidate, initiate or modify its positions.
The Fund presents a risk of loss of capital. Please refer to the Fund’s prospectus to view the exhaustive list of risks.

Fees

ISIN: LU2585801330
Entry costs
We do not charge an entry fee. 
Exit costs
We do not charge an exit fee for this product.
Management fees and other administrative or operating costs
1.12% of the value of your investment per year. This estimate is based on actual costs over the past year.
Performance fees
20.00% max. of the outperformance if the performance is positive and the net asset value exceeds the high-water mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
Transaction Cost
0.23% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.

Performance

ISIN: LU2585801330
Carmignac Portfolio Merger Arbitrage Plus+2.3+4.6+3.7+3.2
Carmignac Portfolio Merger Arbitrage Plus+3.0%+3.7%+3.9%

Source: Carmignac at 30 Oct 2026.
Date of 1st NAV : 14/04/2023.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Fund presents a risk of loss of capital.
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference Indicator: -

Share

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com/en, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

  • In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.com/en-gb, or upon request to the Management Company, or for the French Funds, at the offices of the acilities Agent, Carmignac UK Ltd, 2 Carlton House Terrace, London, SW1Y 5AF. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

  • In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.com/en-ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

  • In Belgium: This document is intended for professional clients. This content has not been validated by FSMA. The decision to invest in the promoted fund should take into account all its characteristics or objectives as described in its prospectus. This communication is published by Carmignac Gestion S.A., a portfolio management company approved by the Autorité des Marchés Financiers (AMF) in France, and its Luxembourg subsidiary Carmignac Gestion Luxembourg, S.A., an investment fund management company approved by the Commission de Surveillance du Secteur Financier (CSSF). “Carmignac” is a registered trademark. “Investing in your Interest” is a slogan associated with the Carmignac trademark. This document does not constitute advice on any investment or arbitrage of transferable securities or any other asset management or investment product or service. The information and opinions contained in this document do not take into account investors’ specific individual circumstances and must never be interpreted as legal, tax or investment advice. The information contained in this document may be partial and could be changed without notice. This document may not be reproduced in whole or in part without prior authorisation. The risks and fees are described in the KID (Key Information Document). The prospectus, KID, the net asset-values and the latest (semi-) annual management report may be obtained, free of charge, in French or in Dutch, from the management company (tel. +352 46 70 60 1) or by consulting its website or www.fundinfo.com. These materials may also be obtained from Caceis Belgium S.A., the financial service provider in Belgium, at the following address: avenue du port, 86c b320, B-1000 Brussels. The Fund (fonds commun de placement or FCP) is a common fund in contractual form conforming to the UCITS Directive under French law. Access to the Fund may be subject to restrictions regarding certain persons or countries. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. In case of subscription to a fund subject to Article 19bis of the Belgian Income Tax Code (CIR92), the investor will have to pay, upon redemption of his or her shares, a withholding tax of 30% on the income (in the form of interest, or capital gains or losses) derived from the return on assets invested in debt claims. Distributions are subject to withholding tax of 30% without income distinction. In case of subscription in a French investment fund (fonds commun de placement or FCP), you must declare on tax form, each year, the share of the dividends (and interest, if applicable) received by the Fund. Any complaint may be referred to complaints@carmignac.com or CARMIGNAC GESTION - Compliance and Internal Controls - 24 place Vendôme Paris France or on the website www.ombudsfin.be.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights at section 5 entitled "summary of investor rights" on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden. Belgium (French) ; Belgium (Dutch)

For Carmignac Portfolio Long-Short European Equities: Carmignac Gestion Luxembourg SA in its capacity as the Management Company for Carmignac Portfolio, has delegated the investment management of this Sub-Fund to White Creek Capital LLP (Registered in England and Wales with number OCC447169) from 2nd May 2024. White Creek Capital LLP is authorised and regulated by the Financial Conduct Authority with FRN : 998349.

Carmignac Private Evergreen refers to the Private Evergreen sub-fund of the SICAV Carmignac S.A. SICAV – PART II UCI, registered with the Luxembourg RCS under number B285278.